All In Biotech

Drug Trial Radar · NCT02426034

A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study

Last checked: Nov 19, 2026Latest source record: Jul 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,004

Actual

Start

May 15, 2015

Primary completion

May 29, 2020

Study completion Sep 3, 2020

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The large-scale phase IV study aims to verify the safety and efficacy of apatinib in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma after failure of two lines of chemotherapy. Apatinib initiated at a recommended dose of 850mg. However, the starting dose was decided by investigator's choice based on patients' condition. Dose interruption and dose reduction were allowed according to the product label. Treatment continued until disease progression, intolerable toxicity, withdrawal of informed consent, or at investigators' discretion. The primary endpoint was safety, which was assessed by recording the incidence and severity of adverse events.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • ApatinibTabletsDrug

    Apatinib Tablets, recommended dose of 850mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety, which was assessed by recording the incidence and severity of adverse eventsTime frame: between first dose of apatinib and up to 30 days after the last dose of apatinib

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nanjin Military 81 Hosiptal

    Nanjing, Jiangsu, China

  • Fudan University cancer hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.